10+ hour, 45+ min ago  (239+ words) citybuzz - VERAXA Biotech (NASDAQ: VRXA) announced new in vitro proof-of-concept data for its Bi TAC-ADC technology platform, which the company says could improve precision in cancer treatment by restricting therapeutic activation to tumors. The data, released on June 19, 2026, show that…...